Sorafenib, an approved multikinase inhibitor for patients with advanced stage of hepatocellular carcinoma (HCC), acts as an autophagy inducer by inhibiting mTORC1 [167] or activating AKT pathway [168], causing cell death or survival [169]. Here, AKT1 is linked to hepatocellular carcinoma.